




The relative strengths and weaknesses of Bellerophon Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bellerophon Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Bellerophon Therapeutics Inc is the variable Net Income, reducing the Economic Capital Ratio by 85% points.

The company's Economic Capital Ratio, given in the ranking table, is 218%, being 45% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	29,452
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,073
Liabilities, Non-Current	0
Other Assets	7,158
Other Compr. Net Income	-19
Other Expenses	0
Other Liabilities	0
Other Net Income	109
Other Revenues	1,667
Property and Equipment	1,799
Research and Development	33,365
Selling, General and Administrative Expense	14,870

Output Variable	Value in 1000 USD
Assets	38,409
Liabilities	8,073
Expenses	48,235
Revenues	1,667
Stockholders Equity	30,336
Net Income	-46,459
Comprehensive Net Income	-46,468
BaseVar	48,256
ECR before LimitedLiability	85%
Economic Capital Ratio	218%